A clinical trial assessing deucrictibant in acquired angioedema due to C1-INH deficiency (AAE-C1INH)
Latest Information Update: 17 Jan 2025
Price :
$35 *
At a glance
- Drugs Deucrictibant (Primary)
- Indications Angioedema
- Focus Adverse reactions
- 17 Jan 2025 New trial record
- 13 Jan 2025 According to Pharvaris media release, study initiation of deucrictibant for the treatment of acquired angioedema due to C1-INH deficiency (AAE-C1INH) anticipated in 2025